

Ross Camidge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8823007/publications.pdf>

Version: 2024-02-01

16
papers

1,559
citations

623734

14
h-index

940533

16
g-index

16
all docs

16
docs citations

16
times ranked

2267
citing authors

#	ARTICLE	IF	CITATIONS
1	Managing Central Nervous System Spread of Lung Cancer: The State of the Art. <i>Journal of Clinical Oncology</i> , 2022, 40, 642-660.	1.6	23
2	COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3383-3393.	1.6	120
3	Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. <i>Journal of Clinical Oncology</i> , 2021, 39, 2791-2802.	1.6	32
4	Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 139, 60-67.	2.0	88
5	Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. <i>Cancer Treatment and Research Communications</i> , 2019, 19, 100126.	1.7	24
6	Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 341-355.	27.6	347
7	Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2018, 13, 134-138.	1.1	21
8	Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitor. <i>Lung Cancer</i> , 2018, 126, 112-118.	2.0	14
9	First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance. <i>Clinical Lung Cancer</i> , 2018, 19, 531-543.	2.6	3
10	Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1293-1304.	1.1	143
11	Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 307-319.	2.3	18
12	Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. <i>Cancer</i> , 2013, 119, 2383-2390.	4.1	45
13	Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer. <i>Cancer</i> , 2013, 119, 3968-3975.	4.1	47
14	Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive non-small cell lung cancer. <i>Cancer</i> , 2012, 118, 4486-4494.	4.1	88
15	Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed. <i>Journal of Thoracic Oncology</i> , 2011, 6, 774-780.	1.1	221
16	Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment. <i>Clinical Cancer Research</i> , 2010, 16, 5581-5590.	7.0	325